The Israeli company Panaxia has announced that it has exported its first sublingual cannabis tablets intended for French experimentation with therapeutic cannabis.
According to the company’s statement, Naxiva-Panaxir tablets contribute “to better response to treatment and greater patient satisfaction, primarily due to treatment efficacy, simplicity and accuracy of use “.
Dr. Dadi Segal, CEO of Panaxia Israel, said, “We are pleased to take another important step in implementing our strategy. We are proud to be part, alongside our partner, Neuraxpharm, of the spearhead of the main global cannabis players selected for the ANSM program. »
“In addition, we are the only company in this program to provide sublingual medical cannabis tablets. According to our forecasts, the French market should become one of the most advanced medical cannabis markets in the world, which will be a remarkable engine of growth for Panaxia. »
Panaxia had been selected for two batches of medical cannabis:
- Oral form to ingest THC > 5 mg/ml, CBD < 1 mg/ml (Panaxir T20/C0)
- Oral form to ingest THC and CBD > 5 mg/ml (Panaxir T10/C10)
Managing Director of Neuraxpharm France, Dr Pierre-Hervé Brun, said: “It is a great achievement for us, together with our partner Panaxia, to have been selected as one of the few specialists to offer medical cannabis on the French market as part of the ANSM program”.
“As the only companies in the program offering sublingual medical cannabis tablets, we are able to offer our patients a variety of patient-oriented and easier-to-use presentation forms. Going forward, we will continue to work with Panaxia to further our strategy in the growing medical cannabis sector and bring innovative forms of consumption to market.”
French experimentation with medical cannabis began with the dispensing of CBD and/or THC oils, then flowers last summer.
